13 Pharmaceuticals Stocks to Sell Now

13 Pharmaceuticals Stocks to Sell Now

By Portfolio Grader

http://bit.ly/2ffU2f6

The ratings of 13 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

GlaxoSmithKline plc Sponsored ADR (GSK) experiences a ratings drop this week, going from last week’s C to a D. GlaxoSmithKline plc Sponsored ADR is a research-based pharmaceutical company. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of GSK stock.

Mylan N.V. (MYL) gets weaker ratings this week as last week’s D drops to a F. Mylan N.V. is a global generic and specialty pharmaceuticals company. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MYL stock.

This week, Astrazeneca PLC Sponsored ADR (AZN) drops from a D to a F rating. Astrazeneca PLC Sponsored ADR is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. The company also gets F’s in sales growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AZN stock.

Akorn, Inc. (AKRX) slips from a C to a D this week. Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. For more information, get Portfolio Grader’s complete analysis of AKRX stock.

Nektar Therapeutics (NKTR) earns a D this week, moving down from last week’s grade of C. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The company also gets F’s in sales growth. For more information, get Portfolio Grader’s complete analysis of NKTR stock.

Slipping from a C to a D rating, RedHill Biopharma Ltd. Sponsored ADR (RDHL) takes a hit this week. The company also gets F’s in sales growth, earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RDHL stock.

This week, Agile Therapeutics, Inc.’s (AGRX) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGRX stock.

This is a rough week for Oramed Pharmaceuticals Inc. (ORMP). The company’s rating falls to D from the previous week’s C. Oramed Pharmaceuticals Inc. is a pharmaceutical company focused on the development of oral delivery solution. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ORMP stock.

Juniper Pharmaceuticals, Inc. (JNP) declines this week from a D to a F. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of JNP stock.

MediWound Ltd. (MDWD) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MDWD stock.

KemPharm, Inc.’s (KMPH) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of KMPH stock.

Orexigen Therapeutics, Inc. (OREX) gets weaker ratings this week as last week’s D drops to a F. Orexigen Therapeutics, Inc. is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system disorders with an initial focus on obesity. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OREX stock.

This week, Marinus Pharmaceuticals Inc’s (MRNS) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRNS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/11/13-pharmaceuticals-stocks-to-sell-now-3/.

©2018 InvestorPlace Media, LLC